Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Novavax Booster in Immunosuppressed IBD and Transplant Patients
NCT06027229Phase 2Completed
- Sponsor
- University of Wisconsin–Madison
- Start
- Nov 2023
- Primary completion
- Apr 2024
- Modality
- Recombinant Proteins and Enzymes, Nanoparticles, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of NVX-CoV2373 in coronavirus disease 2019 (COVID-19), sponsored by University of Wisconsin–Madison. Started Nov 2023; status: completed.
02
Drugs
NVX-CoV2373
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06027229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06027229.